3Safarinejad MR.Prevalence of benign prostatic hyperplasia in a population-based study in Iranian men 40 years old or older[J] ,Int Urol Nephrol,2008,40(4):921-931.
4Hayashi T,Sakai Y,Saito K,et al.A comparative study assessing clinical effects of naftopidil and tamsulosin hydrochloride on benign prostatic hyperplasia[J].Hinyokika Kiyo,2002,48(1):7-11.
5Matsubara Y,Kanazawa T,Kojima Y,et al.Pharmacokinetics and disposition of silodosin(KMD-3213)[J].Yakugaku Zasshi,2006,126:237.
6Roehrborn CG,Siami P,Barkin J,et al.The influence of baseline parameters on changes in international prostate symptom score with dutasteride,tamsulosin,and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate:2-year data from the combat study[J].Eur Urol,2009,55(2):461-471.
7Rick FG,Schally AV,Block NL,et al.LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia[J].Prostate,2010:Epub ahead of print.
8Muthyala R,Ju Y,Sheng S,et al.Equol,a natural estrogenic metabolite from soy isoflavones:convenient preparation and resolution of R-and S-equols and their differing binding and biological activity through estrogen receptors alpha and beta[J].Bioorg Med Chem,2004,12(6):1559-1567.
9Gonzalez G,Guendulain C,Maffrand C,et al.Comparison of the effect of the aromatase inhibitor,anastrazole,to the antioestrogen,tamoxifen citrate,on canine prostate and semen[J].Reprod Domest Anim,2009,44(Suppl 2):316-319.
10Paick J,Kim S,Yang D,et al.The efficacy and safety of udenafil,a new selective phosphodiesterase type 5 inhibitor,in patients with erectile dysfunction[J].J Sexual Med,2008,5(4):946-953.
